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Abstract
Background: Conflicting results have been reported on the influence of carbohydrates in breast cancer.
Objective: To determine the influence of pre-operative per-oral carbohydrate load on proliferation in breast
tumors.
Design: Randomized controlled trial.
Setting: University hospital with primary and secondary care functions in South-West Norway.
Patients: Sixty-one patients with operable breast cancer from a population-based cohort.
Intervention: Per-oral carbohydrate load (preOp™) 18 and 2–4 h before surgery (n = 26) or standard pre-operative
fasting with free consumption of tap water (n = 35).
Measurements: The primary outcome was post-operative tumor proliferation measured by the mitotic activity
index (MAI). The secondary outcomes were changes in the levels of serum insulin, insulin-c-peptide, glucose, IGF-1,
and IGFBP3; patients’ well-being, and clinical outcome over a median follow-up of 88 months (range 33–97
months).
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Results: In the estrogen receptor (ER) positive subgroup (n = 50), high proliferation (MAI ≥ 10) occurred more often
in the carbohydrate group (CH) than in the fasting group (p = 0.038). The CH group was more frequently
progesterone receptor (PR) negative (p = 0.014). The CH group had a significant increase in insulin (+ 24.31 mIE/L,
95% CI 15.34 mIE/L to 33.27 mIE/L) and insulin c-peptide (+ 1.39 nM, 95% CI 1.03 nM to 1.77 nM), but reduced
IGFBP3 levels (− 0.26 nM; 95% CI − 0.46 nM to − 0.051 nM) compared to the fasting group. CH-intervention ER-
positive patients had poorer relapse-free survival (73%) than the fasting group (100%; p = 0.012; HR = 9.3, 95% CI, 1.1
to 77.7). In the ER-positive patients, only tumor size (p = 0.021; HR = 6.07, 95% CI 1.31 to 28.03) and the CH/fasting
subgrouping (p = 0.040; HR = 9.30, 95% CI 1.11 to 77.82) had independent prognostic value. The adverse clinical
outcome of carbohydrate loading occurred only in T2 patients with relapse-free survival of 100% in the fasting
group vs. 33% in the CH group (p = 0.015; HR = inf). The CH group reported less pain on days 5 and 6 than the
control group (p < 0.001) but otherwise exhibited no factors related to well-being.
Limitation: Only applicable to T2 tumors in patients with ER-positive breast cancer.
Conclusions: Pre-operative carbohydrate load increases proliferation and PR-negativity in ER-positive patients and
worsens clinical outcome in ER-positive T2 patients.
Trial registration: CliniTrials.gov; NCT03886389. Retrospectively registered March 22, 2019.
Keywords: Breast cancer, Carbohydrate load, Proliferation, Insulin, Insulin c-peptide, IGF-1, IGFBP3, Tumor size,
Relapse-free survival, Breast cancer-specific survival
Background
Breast cancer is the most frequent malignancy among
women [1], representing 12% of all new cancer cases
and 25% of all cancers in women worldwide [2, 3]. In
Norway, the incidence of breast cancer has doubled dur-
ing the last 50 years. The lifetime risk for a Norwegian
woman developing the disease is 10–12% [4]. A total of
570,000 women across the globe died of breast cancer in
2015, comprising 15% of cancer deaths among women
[3]. Approximately 75% of all new breast cancers are
luminal breast cancer subtypes, which express estrogen
receptor (ER) and/or progesterone receptor (PR) [5].
The etiological factors of breast cancer comprise genetic,
hormonal, environmental, and lifestyle-related elements
[6]. Risk factors relating to the Western lifestyle, includ-
ing lack of physical exercise, being overweight, certain
hormonal and dietary factors, and diabetes mellitus type
2, have recently gained increased attention [2].
The effect of carbohydrate consumption on breast can-
cer incidence and outcome is probably mediated through
three parallel routes. One route is through stimulation of
the insulin/ insulin-like growth factor-1 (IGF-1) axis in
epithelial breast cells, which comprises the insulin recep-
tor (IR) [7] and IGF1 signaling pathways [8]. This results
in crosstalk between cellular signaling systems and endo-
crine resistance in luminal breast cancers (i.e., ER-positive
tumors) [9, 10]. Secondly, a substantial part of the insulin
effect is mediated by paracrine signaling in the tumor
micro-environment between adjacent adipocytes, fibro-
blasts, and the epithelial cancer cell. Signaling factors, such
as ER, IR, IGF1-R, adiponectin, and leptin are involved
[11]. Thirdly, alimentary glucose may affect cancer cells
directly through the Warburg effect, which is an expedient
switch that changes cellular energy metabolism from
oxidative mitochondrial ATP production to cytoplasmic
aerobic glycolysis [12]. This transition enables the prolifer-
ative cancer cells to produce both ATP for energy and
ribose for DNA synthesis [13].
In human breast cancer patients, studies on the rela-
tionship between carbohydrate/glucose content in food
and quantitative insulin characteristics are lacking. Insu-
lin is a growth factor that increases proliferation and
decreases apoptosis, and elevated levels of insulin are as-
sociated with different cancers, including breast cancer
[14]. In breast cancer patients without diabetes, high in-
sulin levels have been associated with a poor prognosis
[15]. Insulin receptors have been detected on breast can-
cer cells [16], though there is conflicting evidence on
whether insulin directly regulates cancer proliferation,
and how fast such an effect will occur. Also, there is a re-
search deficit on the influence of carbohydrates on clinical
outcome or prognostic endpoint biomarkers such as pro-
liferation. Generally, proliferation is measured by the mi-
totic activity index (MAI), phosphohistone-H3 (PPH3),
and Ki-67 [17, 18]. The MAI and PPH3 estimate the num-
ber of cells in M phase (mitosis) and G2M phase, respect-
ively, whereas Ki-67 detects all cells outside the G0phase.
Notably, insulin influences cell cycle kinetics by more
rapid transit through the G1 phase in ER-positive cells [7].
A meta-analysis has shown that, in patients undergo-
ing abdominal surgery, administration of two per-oral
carbohydrate loads administered 12–18 h, and again 2–
4 h, before elective surgery reduces postoperative insulin
resistance and leads to enhanced recovery after surgery
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(ERAS) [19]. During surgery, however, breast cancer
cells are pushed into the circulation [20]. Moreover, due
to the pre-operative oral carbohydrate load used in
ERAS protocols, these cells may have a much better
chance of survival and of forming viable metastatic foci
[21, 22]. Pre-operative oral hyperglycemic loading may
bring breast cancer cells into a favorable state to escape,
divide, thrive, and survive during surgery, which may
then lead to an inferior long-term prognosis for breast
cancer patients [23]. Therefore, it is of great importance
to gain more insight into the effects of pre-operative
carbohydrate administration in breast cancer regarding
insulin-related characteristics, proliferation, and clinical
outcomes.
The cell cycle in breast cancer is fast enough to be
influenced by the two pre-operative oral carbohydrate
loads in ERAS protocols [24, 25]. We chose to use the
MAI as our primary endpoint for proliferation. Our
hypotheses were that an ERAS protocol comprising two
oral carbohydrate loads will improve post-surgical recov-
ery in breast cancer patients, the oral carbohydrate load
will stimulate cellular signaling and increase proliferation
as measured by the MAI, and pre-operative carbohy-
drate loading will lead to an adverse prognosis in breast
cancer patients. A subgroup analysis of ER-positive pa-
tients was planned before the study was started.
Thus, the aim of this study was to investigate whether
a pre-operative carbohydrate load according to a stand-
ard ERAS protocol influences tumor proliferation, post-
surgical recovery, and/or clinical outcome.
Methods
This population-based cohort of operable breast cancer
patients was randomized into an intervention group re-
ceiving pre-operative per-oral carbohydrate loading or a
control group comprising the standard fasting pre-
operative protocol with unlimited access to drinking
water. The investigation was an open-labeled study for
the patient and breast surgeon. However, all researchers
at the Department of Pathology and hormone laboratory
were blinded to the intervention.
Patients
A total of 253 patients were assessed for eligibility be-
tween May 12, 2009, and June 23, 2010, in the catch-
ment area of Stavanger University Hospital in South-
West Norway. The exclusion criteria were clinical or
radiological T3–4 tumors at clinical examination, overt
systemic metastases, ductal carcinoma in situ (DCIS),
micro-invasive cancer < 2 mm, or comorbidity, including
diabetes mellitus type I and II, Cushing syndrome, previ-
ously diagnosed cancer, or being unable to co-operate in
the study (e.g., dementia, other serious psychiatric ill-
nesses, language barriers, or unwillingness to sign the
informed consent papers). A total of 80 patients with
unequivocal operable breast cancers (Stage I and II) di-
agnosed by fine needle aspiration cytology (FNAC)
agreed to participate in the study and were randomized
(Fig. 1). The last follow-up date was June 28, 2017. A lar-
ger proportion of dropouts in the intervention group for
various random reasons created an imbalance in the
numbers of patients between allocation groups (Fig. 1).
Randomization and intervention
Randomization was performed after the patients pro-
vided written consent to participate in the study. The
randomization procedure was organized as an in-house
procedure with concealed envelopes generated and dis-
tributed in two boxes by the study nurse. The allocation
sequence was performed by the trial administration
committee. The sequence was balanced according to age
by choosing between two boxes, one for age < 55 years
(i.e., possible and certain premenopausal) and one for
age ≥ 55 years (i.e., most probably postmenopausal), each
with 1:1 block randomization regarding the carbohydrate
(intervention) and fasting (control) groups in each box.
The surgeon in the out-patient clinic enrolled consecu-
tively operable breast cancer patients who agreed to par-
ticipate in the trial.
Intervention
Patients who were randomized to pre-operative carbohy-
drates drank 400 ml pre-Op™ (Nutricia, Netherlands)
containing 12% carbohydrates, 2% glucose, and 10%
polysaccharides the evening before (i.e., 18 h before sur-
gery) and in the morning on the day of the operation
(i.e., 2–4 h before surgery). Each patient was asked be-
fore surgery if they had been able to finish the carbohy-
drate drink or if they were fasting according to the
randomization. The control group followed the standard
fasting procedure with free intake of tap water.
Blinding
The study was not blinded for the patients due to use of
the carbohydrates and tap water by the participants. The
information on the grouping was known only to THL,
who was head of the clinical part of the trial, and this in-
formation was kept in a locked safe. Others involved in
the study had no access to this information. Thus, the
investigation was blinded for the laboratory personnel
performing various assessments (MAI, PPH3, Ki67,
histological grading, insulin, C-peptide etc.).
Primary treatment
The primary surgery was performed according to the
recommendations of the Norwegian Breast Cancer
Group (NBCG) [4]. The surgery was either breast con-
serving treatment (BCT) or mastectomy, and sentinel
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node (SN) diagnostic or axillary lymph node clearance of
level I and II. Adjuvant chemotherapy was also given
based on the NBCG guidelines [4]. Notably, we found
no differences between the two allocation groups regard-
ing the type of primary treatment received (Table 1).
Safety issues
The patients were hospitalized for 1–2 days after sur-
gery. Any complications, such as hemorrhage, infection,
or others, were recorded on the Case Report Forms. No
patients died or experienced any serious complications
from the pre-operative treatment.
Blood sampling for serum analysis
Five blood samples were obtained from the participants:
1) at the time of diagnosis, 2) at admission (the day be-
fore surgery), 3) pre-operatively before surgery, after the
second pre-Op™ carbohydrate dose, 4) the day after
Fig. 1 Study flow diagram
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Table 1 Baseline characteristics of patients in the two study groups
Variable Carbohydrate group
(n = 26)





n (%) n (%)
Age
< 55 12 (46) 0 16 (46) 0 0.973
> 55 14 (54) 0 19 (54) 0
BMI (kg/m2) 25.0 (3.9) 4 25.1 (3.0) 3 0.868
BMI < 25a 14 (64) 4 17 (53) 3 0.443
BMI≥ 25 8 (36) 15 (47)
BMI < 75 percentileb 18 (82) 4 23 (76) 3
BMI≥ 75 percentile 4 (18) 13 (24) 0.401
Menopausal status
Premenopausal 4 (17) 1 7 (22) 1 0.627
Postmenopausal 20 (83) 1 25 (78) 2
HRT - yes 8 (35) 3 10 (32) 4 0.937
HRT – no 14 (61) 19 (61)
HRT- not relevant 1 (4) 2 (7)
HRT use (years) 4.7 (4.3) 16 7.9 (5.8) 25 0.176
Tumor size (mm) 19.4 0 15.0 0 0.094
Tumor category
T1 16 (62) 0 29 (83) 0
T2 10 (38) 0 6 (17) 0 0.061
Histological Gradec 0.157
1 4 (15) 0 7 (20) 0
2 10 (39) 0 20 (57) 0
3 12 (46) 0 8 (23) 0
pN negative 18 (69) 0 25 (71) 0 0.852
pN positive 8 (31) 0 10 (29) 0
Number LNs removed 5.5 2 5.8 0 0.843
Number positive LNs 0.38 2 0.86 0 0.191
Estrogen receptor
Positive (≥1%) 21 (81) 0 29 (83) 0 0.834
Negative (< 1%) 5 (19) 0 6 (17) 0
Progesterone receptor
Positive (≥ 10%) 13 (50) 0 28 (80) 0 0.014
Negative (< 10%) 13 (50) 0 7 (20) 0
HER2
Positive 3 (12) 0 1 (3) 0 0.176
Negative 23 (88) 0 34 (97) 0
MAI (median, IQR) 7 (2–9) 1 5 (2–9) 0 0.647
MAI < 10 14 (56) 1 27 (77) 0
MAI≥ 10 11 (44) 8 (23) 0 0.083
Ki67 (mean, SD) 30.4 (28.2) 0 28.0 (26.5) 1 0.747
Ki67 < 15% 9 (35) 0 17 (50) 1
Ki67≥ 15% 17 (65) 0 17 (50) 0 0.233
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Table 1 Baseline characteristics of patients in the two study groups (Continued)
Variable Carbohydrate group
(n = 26)





n (%) n (%)
Ki67 < 30% 14 (54) 0 24 (71) 1 0.182
Ki67≥ 30% 12 (46) 0 10 (29) 0
PPH3 (mean, SD) 20.2 (24.7) 0 20.5 (26.9) 0 0.966
PPH3 < 13 14 (54) 0 21 (60) 0 0.631
PPH3≥ 13 12 (46) 0 14 (40) 0
TILs (mean %, SD) 4.7 (10.7) 0 4.3 (7.3) 1 0.137
TILs
Positive (> 10%) 2 (8) 0 4 (11) 0 0.663
Negative (< 10%) 24 (92) 0 31 (89) 0
Luminal typed
Luminal A 16 (62) 0 23 (66) 0
Luminal B 10 (38) 0 12 (34) 0 0.737
Glucose
Admissione| 5.4 (1.1) 0 5.3 (0.6) 0 0.864
Pre-operativef 5.2 (1.8) 0 5.1 (0.6) 0 0.739
S-Insulin
Admissione 9.4 (8.5) 0 9.1 (6.6) 0 0.886
Pre-operativef 33.7 (20.2) 0 9.1 (5.9) 0 < 0.0001
S-insulin-c-peptide
Admissione 0.69 (0.32) 0 0.75 (0.32) 0 0.517
Pre-operativef 2.10 (1.05) 0 0.75 (0.27) 0 < 0.0001
Surgery
BCT 15 (58) 0 23 (66) 0
Mastectomy 11 (42) 0 12 (34) 0 0.523
Axillary staging
SN 21 (81) 0 28 (80) 0
ALND 5 (19) 0 7 (20) 0 0.940
Reoperation - 1
-Breast 1 (20) 0 1 (50) 0
-Axilla 4 (80) 0 1 (50) 0 0.427
Chemo therapy
Yes 12 (46) 0 17 (47) 0
No 14 (53) 0 18 (51) 0 0.852
Radiation therapy
Yes 17 (68) 0 26 (74) 0
No 8 (32) 1 9 (26) 0 0.594
Endocrine therapy
Yes 17 (65) 0 22 (63) 0
No 9 (35) 0 13 (37) 0 0.839
Smoking status 5 4
-Never smoked 5 (24) 10 (32) 0.650
-Former smoker 9 (43) 14 (45)
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surgery, and 5) 4 weeks post-surgery. Immediately after
being drawn, the blood samples were put in ice water
for transport to the in-house medical laboratory. The
samples were spun and the serum frozen for transport
to the Hormone Laboratory, Haukeland University Hos-
pital, Bergen, Norway, where insulin, insulin c-peptide,
IGF-1, and IGFBP-3 were measured by the IMMULITE
2000 two-site chemiluminescent immunometric assay
(Siemens Medical Solutions Diagnostics).
Histology
Tumor size was measured macroscopically in fresh spec-
imens following excision. The tissues were cut into 0.5-
cm slices. The axillary lymph nodes from sentinel node
biopsy, or axillary fat from axillary dissection were ex-
amined macroscopically by a pathologist. All detectable
lymph nodes (median 3 per patients, range 1–21) were
prepared for histological examination. No lymph nodes
were detected in two patients. For hematoxylin–eosin–
saffron (HES) staining, the tissues were fixed in buffered
4% formaldehyde, embedded in paraffin, and sectioned
(4 μm). The histological type and grade were assessed
according to World Health Organization criteria (by two
pathologists, EG and JPAB) [26].
Immunohistochemistry
Immunohistochemistry (IHC) was performed to identify
ER, PR, PPH3, Ki-67, and human epidermal growth
factor receptor 2 (HER2) in whole sections. The antigen
retrieval and IHC techniques were based on DAKO
technology [27]. Formalin-fixed paraffin-embedded
(FFPE) sections (4-μm thick) were serially sectioned after
the preparation of HES sections and mounted onto sili-
conized slides (#S3002, DAKO, Glostrup, Denmark). A
highly stabilized retrieval system (ImmunoPrep; Instru-
mec, Oslo, Norway) was used for antigen retrieval with
the retrieval buffer (10 mM Tris/1 mM EDTA, pH 9.0).
Sections were heated for 3 min at 110 °C, and then 10
min at 95 °C, before cooling to 20 °C. The following anti-
bodies and dilutions were used: ER (clone SP1,
Neomarkers/LabVision, Fremont, CA, USA), 1:400; PR
(clone SP2, Neomarkers/LabVision), 1:1000; rabbit poly-
clonal anti-PPH3 (ser 10) (Upstate #06–570; Lake Placid,
NY), 1:1500; and Ki-67 (clone MIB-1, DAKO, Glostrup,
Denmark), 1:100. All antibodies were incubated for 30
min at 22 °C. Visualization was achieved using the
EnVision™ FLEX detection system (DAKO, K8000). Sec-
tions were incubated with the peroxidase-blocking re-
agent (SM801) for 5 min, followed by the primary
antibody for 30 min, EnVision™ FLEX/HRP Detection
Reagent (SM802) for 20 min, EnVision™ FLEX DAB+
Chromogen (DM827)/EnVision™ FLEX Substrate Buffer
(SM803) mix for 10 min, and EnVision™ FLEX
Hematoxylin (K8008) for 5 min. Next, the slides were
dehydrated, mounted, and stained using a Dako Auto-
stainer Link 48 instrument and EnVision™ FLEX Wash
Buffer (DM831). To assess HER2, the DAKO HercepT-
est™ was used according to the manufacturer’s protocol.
Quantitative measures
MAI was assessed as the total number of mitotic figures
in 10 consecutive fields of vision at 400× magnification
(objective 40, specimen level field diameter 450 μm) in
the most poorly differentiated periphery of the tumor,
representing a total area of 1.59 mm2. Areas with necro-
sis or inflammation were avoided. This was performed
as a routine diagnostic procedure, but controlled by EJ
as described elsewhere [28]. We assessed the PPH3
index as described previously [29] and evaluated PPH3
expression using the fully automated VIS analysis system
(Visiopharm, Hørsholm, Denmark) and previously de-
scribed image processing principles [27]. The semi-
automatic interactive computerized QPRODIT system
(Leica, Cambridge) was used to measure the percentage
of Ki-67-positive cells as described elsewhere [30]. A
total of 250–350 fields of vision were systematically se-
lected at random for each measurement. The Ki-67 per-
centage was defined as [(Ki-67 positive)/ (Ki-67 positive
+ Ki-67 negative)] × 100. ER-positivity was the presence
of nuclear staining in > 1% of the cancer cells and ER-
Table 1 Baseline characteristics of patients in the two study groups (Continued)
Variable Carbohydrate group
(n = 26)





n (%) n (%)
-Ongoing smoking 7 (33) 7 (23)
Tumor size category analyzed as T1 vs. T2
aBMI-25 represents a dichotomized BMI < 25 or ≥ 25 on the BMI scale
bBMI-75p represents a dichotomized BMI with cut off < /≥ 75 percentile, i.e., </≥ 26.8 on the BMI scale
cHistological grading was performed according to the Nottingham algorithm
dLuminal A = ER+/HER2−/Ki67 < 15% and Luminal B = ER+/HER2−/Ki67 ≥ 15%
eBlood samples taken in the fasting state at the time patients were admitted in the hospital approx. 24–30 h before surgery
fPre-operative blood samples taken 1–2 h before the surgical procedure commenced
BMI Body mass index, HRT Hormonal replacement therapy, pT Pathological tumor size in mm or category, pN Pathological lymph node status, LN Lymph node,
HER-2 Human epidermal growth factor receptor 2, MAI Mitotic activity index, TILs Tumor infiltrating leucocytes, PPH3 Phosphorylated phospho-histone 3, SN
Sentinel node, ALND Axillary lymph node dissection
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negative when < 1% of the cells were stained. For PR,
positive was defined as nuclear staining present in > 10%
of the cancer cells, borderline as 1–10% of the cancer
cells exhibiting nuclear staining, and negative as < 1% of
the epithelial breast cancer cells exhibiting nuclear stain-
ing. The DAKO Hercep-Test scoring protocol was used
to score HER2, with 2+ and 3+ cases considered to be
positive. Two of the authors (BH and EJ) scored all
sections independently.
The relative number of stromal tumor-infiltrating lym-
phocytes (TILs) was assessed according to Salgado et al.
[31]. HE-stained tissue sections were scored semi-
quantitatively according to the presence or absence of
stromal TILs. The degree of infiltration was scored from
0 to 100%, with positive TILs defined as ≥10%. Tumors
were also classified as luminal A (ER+/HER2−/Ki67 <
15%) or luminal B (ER+/HER2−/Ki67 ≥ 15% or ER+/
HER2+ regardless of Ki67) cancers according to the St.
Gallen 2013 recommendations [32].
Main outcome measures
The main primary outcome measure was the difference
in proliferation (measured by MAI) in the primary
tumor between the study groups. The secondary out-
come measures were differences in insulin-related char-
acteristics (i.e., insulin/c-peptide, IGF1, and IGFBP3)
between the intervention and control groups. Patient-
reported outcome measures (PROMs) on the following
complaints and symptoms were also regarded as second-
ary outcomes: nausea, pain, mobilization, dizziness,
insecurity, and bleeding. We applied an in-house ques-
tionnaire with which the patients were asked to score
the six variables on a 4-step Likert scale (1 = ‘no’, 2 = ‘lit-
tle’, 3 = ‘moderate’, and 4 = ‘very much’) on days 1, 2, 3,
4, 5, 6, and 7 after the operation.
For long-term outcome measures, we looked at
relapse-free survival (RFS), defined as the time from sur-
gery until the time the patient was diagnosed with a re-
lapse in any location (i.e., locoregional, systemic, or
contralateral). The time from surgery until death due to
breast cancer was the breast cancer-specific survival
(BCSS). The time from surgery until death from any
cause constituted overall survival (OS). For both the
primary and secondary outcomes, a subgroup analysis
was planned for the ER-positive (luminal) breast cancer
subtype.
Statistical analysis
Power calculations were performed on the basis of the
primary endpoint. We anticipated a 20% increase in
MAI in the intervention group compared to the control
group. Based on the mean value of MAI in patients be-
longing to the catchment area of Stavanger University
Hospital [33, 34] and the reproducibility of the method
to assess MAI, a total of 30 patients was needed in each
study group (i.e., 60 patients) to achieve 80% power. We
decided to randomize 80 patients to allow for a 10–15%
drop-out rate.
As ER- positive breast cancer comprises approximately
75% of all breast cancer cases, there should be a reason-
able number of patients to perform a subgroup analysis
of luminal breast cancers. Statistical analyses were per-
formed using SPSS statistical software v.22 (SPSS, Inc.,
Chicago, IL, USA). Differences in the clinical variables
between the intervention groups were determined using
T-tests, Fishers exact test, or chi-squared tests as appro-
priate. Kaplan-Meier survival curves were constructed,
and the log-rank test was used to evaluate survival dif-
ferences between groups. Cox proportional hazard ana-
lysis was used to test the relative importance of potential
prognostic variables. In multivariable Cox regression, a
backward stepwise model selection procedure was used,
in which all covariates deemed clinically relevant were
included in the initial model.
The proportion of patients reporting at least mild
problems on each of the items on the PROM question-
naire each day for the first 7 postoperative days was
analyzed using a mixed effects logistic regression model.
Using this model, we tested for differences between the
intervention and control groups. If a significant differ-
ence was found, a post-hoc analysis was performed using
chi-squared tests for each of the days. We did not apply
any correction for multiple testing due to the pilot and
exploratory nature of the study. A two-tailed P-value of
0.05 was considered the threshold for significance.
Manuscript reporting
We ensure that the manuscript reporting adheres to
CONSORT guidelines for reporting clinical trials, in-
cluding sticking to the CONSORT check list.
Results
The various characteristics of the two allocation groups
are shown in Table 1. Fifty patients had ER-positive tu-
mors and 11 ER-negative tumors. Of the latter, 8 were
HER2-negative (ER-, HER2-) and 4 were triple-negative
(ER-, PR-, HER2-) based on IHC profiling. Notably, we
found no differences in the distribution of the basic co-
variates between the carbohydrate-intervention group
and the fasting group (Table 1).
Proliferation markers
In the total study cohort, none of the continuous vari-
ables (MAI, Ki67, or PPH3) were different between the
carbohydrate and fasting groups. However, when apply-
ing the robust and well-established prognostic threshold
for MAI (< 10/≥10), among the ER-positive patients (n =
50) significantly more patients in the carbohydrate
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intervention (70%) had high proliferation (MAI ≥ 10)
than in the fasting group (30%; p = 0.038; Table 2). The
same trend was found when all tumors were considered
(58% vs. 42%, carbohydrate vs. fasting; p = 0.083). In
lymph node-negative luminal patients, the same correl-
ation was stronger with a Kendall’s tau-b r = 0.488 (p =
0.017), Gamma r = 1.000 (p = 0.017), and Pearson chi-
squared = 7.62 (p = 0.006; Fischer exact = 0.014 (two-
sided); Table 3).
Progesterone receptor
Significantly more patients in the carbohydrate group had
PR-negative tumors (50%) compared to the fasting group
(20%; p = 0.014), independent of luminal A/B status.
Serum glucose and insulin responses
The response to pre-operative carbohydrate loading was
assessed by the difference between the pre-operative
serum values and the values obtained at admission (i.e.,
serum levels after carbohydrate loading minus fasting
baseline values in both groups; Table 4). As expected,
the intervention group had a significant increase in both
S-insulin (+ 24.31 mIE/L, p < 0.0001, 95% CI 15.34 mIE/
L to 33.27 mIE/L) and S-insulin c-peptide (+ 1.39 nM,
p < 0.0001; 95% CI 0.21 nM to 0.97 nM). The upper
quartile (Q4) border value of 2.40 nM was equal to the
upper value of the normal range of insulin c-peptide
(Table 4), indicating that 25% of the patients had c-
peptide values compatible with insulin resistance. Re-
garding IGFBP3, a significant reduction of − 0.43 nM
was measured after carbohydrate loading (p < 0.0001,
95% CI − 0.56 nM to − 0.27 nM) and − 0.26 nM com-
pared to the control group (p = 0.015, 95% CI – 0.46 nM
to – 0.051 nM). We found no changes in S-glucose or S-
IGF-1 values within or between the two study groups
(Table 4, Fig. 2a-f).
Quality of life data
In the carbohydrate intervention group, fewer patients
reported mild and moderate pain during the first 7 post-
operative days than in the fasting group (p < 0.001),
which in post-hoc analysis was significant on postopera-
tive day 5 (28% vs. 47%; p = 0.038) and day 6 (28% vs. 50%;
p < 0.001). Otherwise, there were no significant differ-
ences between the two groups regarding the other items
from the PROM questionnaire (nausea, mobilization, diz-
ziness, insecurity, and bleeding) (data not shown).
Long-term clinical outcome
The median follow-up for RFS was 88months (range 33
to 97months) and for BCSS 88 months (range 45 to 97
months). Eight patients experienced a relapse: one loco-
regional, six systemic, and one contralateral. Five of
these patients died of breast cancer.
Relapse-free survival
Randomization to intervention with pre-operative carbo-
hydrates had a weak and borderline influence on RFS
when analyzed in the whole study cohort (Table 5).
However, in the ER-positive patients who received car-
bohydrates pre-operatively, a reduced RFS of 71% com-
pared to 97% in the control group (p = 0.012, HR = 9.3,
95% CI 1.1 to 77.7; Table 5 and Fig. 3a) was observed.
The covariates tumor diameter between 2 and 5 cm (T2)
and the proliferation marker Ki67 (both ≥15% and ≥
30%) had a significant negative influence on RFS in both
the whole cohort and in the ER-positive cohort (Table 5).
In the ER-negative subgroup, there was no influence of
the carbohydrate/fasting grouping on RFS (Fig. 3b). The
following co-variates were deemed clinically relevant:
tumor size, nodal status, histological grade, PR and
HER2 status, Ki67–15%, Ki67–30%, PPH3–13, MAI-10,
TILs, luminal A/B status, carbohydrate/fasting grouping,
chemotherapy, radiotherapy and endocrine therapy,
BMI-75p, BMI-25, and smoking status. In the multivari-
able analysis, tumor size (T1/T2; p = 0.021, HR = 6.07,
95% CI = 1.31 to 28.03) and carbohydrate/fasting group-
ing (p = 0.040; HR = 9.30, 95% CI 1.11 to 77.82) were the
only two variables left in the final Cox model. As T2 tu-
mors were more frequent in the intervention group, we
performed a Kaplan Meier analysis of the influence of
Table 2 Cross table MAI and allocation groups in ER+ patients
Carbohydrate Fasting Total
MAI < 10 Count 13 26 39
% 65.0% 89.7% 79.6%
MAI≥ 10 Count 7 3 10
% 35.0% 10.3% 21.4%
Total Count 20 29 49
% 100.0% 100.0% 100,0%
Pearson chi-squared: 4.430, df = 1, p = 0.035
Fischer exact: 0.041 (one-sided) and 0.068 (two-sided)
r (gamma) = 0.647 (p = 0.042)
r (Kendall’s tau-b) = 0.301 (p = 0.042)
Table 3 Cross table MAI and allocation groups in ER+ /LN
negative patients
Carbohydrate Fasting Total
MAI < 10 Count 8 20 28
% 66.7% 100.0% 87.5%
MAI≥ 10 Count 4 0 4
% 33.3% 0.0% 12.5%
Total Count 12 20 49
% 100.0% 100.0% 100.0%
Pearson chi-squared: 7.619, df = 1, p = 0.006
Fischer exact: 0.014 (one-sided) and 0.014 (two-sided)
r (gamma) = 1.000 (p = 0.017)
r (Kendall’s tau-b) = 0.488 (p = 0.017)
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Fig. 2 (See legend on next page.)
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the carbohydrate intervention on RFS stratified for T1
vs. T2. This analysis showed that the unfavorable prog-
nostic effect of carbohydrate loading was not present in
the T1 (≤ 2 cm) patients, but was strongly prognostic in
the T2 patients (Fig. 3c and d). In the T2 group, the
carbohydrate-loaded and fasting patients had an RFS of
33 and 100%, respectively (p = 0.031; HR = inf). In the T2
subgroup, there was a significantly higher mean serum
level of pre-operative insulin c-peptide among patients
who experienced a relapse versus those who were
relapse-free (2.02 nM vs. 0.838 nM, p = 0.025). Notably,
there was an even distribution of luminal A and luminal
B tumors among the patients with T2 tumors who expe-
rienced a relapse versus those who did not (p = 0.47).
Breast cancer-specific survival
In the unadjusted analysis of BCSS, intervention with
carbohydrates resulted in a significantly inferior BCSS in
ER-positive patients compared to the control group
(Table 6; Fig. 4a). In ER-positive T2 tumors, the carbo-
hydrate intervention group had the worst BCSS (30%),
compared to 100% in the control fasting group (p =
0.031, HR = infinite, due to zero relapses in one of the
two groups; Fig. 4b). In addition, tumor size, nodal
status, and Ki67–30% provided significant prognostic
information in the unadjusted analysis (Table 6). In the
multivariable analysis, only Ki67–30 remained in the
final model. In general, the small number of patients and
endpoints hampered a robust multivariable analysis.
Overall survival
The univariate analysis of OS in ER+ patients showed
only a borderline significance of OS for the carbohydrate
group (81%) compared to the fasting group (99%; p =
0.068; HR = 6.02; 95% CI 0.672–53.8; Fig. 5a). Only
tumor size remained as an explanatory factor in the final
Cox model (HR = 17.1; 95% CI 17.1–153). In the ER+/
T2 patients, the corresponding OS was 33% vs. 100%, re-
spectively (p = 0.031; HR = inf; Fig. 5b). In the Cox
model, carbohydrate/fasting status was entered in the
last step, but the model was considered too unstable for
a reliable report.
Adverse events
No adverse events were recorded in either of the two study
arms. No signs of pathologically elevated fasting blood
sugar levels (i.e., > 6mmol/L) was noted. Furthermore, in
the carbohydrate arm, no signs of occult diabetes mellitus
were seen (i.e., blood sugar levels > 10mmol/L) after carbo-
hydrate loading.
Discussion
Glucose has been correlated with cancer for nearly a
century. Warburg (1925) was the first to describe the
phenomenon that cancer cells have a much stronger
tendency to take up glucose [35], for which (amongst
other findings) he received the Nobel prize in 1932 [36].
However, to the best of our knowledge, the current
study is the first prospective randomized trial to evaluate
the effects of pre-operative carbohydrate loading on
tumor proliferation and outcome (short-term vs. long-
term) in operable breast cancer patients. In patients with
ER-positive tumors (i.e., luminal tumors), significantly
more patients with MAI ≥ 10 were observed in the
carbohydrate group than the fasting group. Luminal
cancers have, on average, a lower proliferation rate than
ER-negative and triple-negative cancers [37]. As such,
the proliferation-increasing effect of carbohydrate load-
ing in luminal cancers understandably leads to a higher
percentage increase in patients crossing the prognostic-
ally essential MAI-10 threshold. Most ER−/triple-nega-
tive breast cancer patients already have an MAI greatly
exceeding 10. Therefore, carbohydrate loading will prob-
ably not increase proliferation in a clinically significant
manner, as they have an a priori high risk of distant me-
tastases [38]. In addition, the luminal A patients exposed
to excess carbohydrates may turn into luminal B tumors,
thereby statistically increasing their risk for recurrence.
This is in agreement with luminal breast cancers
responding directly to an increase in circulating insulin
through altered transmembrane IRs [39]. Thus, in the
present study, the observation of an increase in insulin/
c-peptide in the intervention group could explain the in-
creased MAI and Ki67 in the ER-positive group. Simi-
larly, as triple-negative cancers better utilize the IGFBP3
pathway in EGF1-signaling [40], the observed reduction
in IGFBP3 after carbohydrate loading may account for
the lack of response to proliferation in the ER-negative
group. This could suggest that the differential responses
to the insulin/IGF1 axis between luminal and triple-
negative cancers [41] explain our observed differences in
response to per-oral carbohydrate loading and mitotic
activity between the ER-positive and ER-negative groups.
(See figure on previous page.)
Fig. 2 Scatterplot of the various insulin-related measures in serum in the two study groups. a S-insulin. b S-insulin c-peptide. c S-IGF. d S-IGFBP3.
e S-glucose. The center of the centroid reference lines represents the mean value in each group (dotted lines). P-values were determined using t-
tests. Units are given by the x-axis and y-axis. All values on the x-axis are at admission, and the y-axis values represent pre-operative
measurements. Red, carbohydrate group; blue, fasting group; S, serum; Preop., pre-operatively; IGF, insulin-like growth factor; IGFBP3, IGF-binding
protein 3
Lende et al. BMC Cancer         (2019) 19:1076 Page 13 of 22
Table 5 Univariable analysis of relapse-free survival
Whole cohort (n = 61) ER positive patients (n = 50)
Characteristics Event/at risk (% survival) Log rank P HR 95% CI Event/at risk (% survival) Log rank P HR 95% CI
Pre-operative randomization
Fasting 2/35 (94) 0.049 1 1/29 (97) 1
Carbohydrates 6/26 (77) 4.4 0.9 to 21.7 6/21 (71) 0.012 9.3 1.1 to 77.7
Nodal status
N0 3/43 (93) 1 3/33 (91) 1
N+ 5/18 (13) 0.03 9.8 1.10 to 88.1 4/17 (77) 0.16 2.8 0.63 to 12.6
Tumor size
T1 3/45 (93) 1 3/39 (92) 1
T2 5/16 (69) 0.009 5.5 1.3 to 23.2 4/11 (64) 0.008 6.0 1.3 to 27.0
Nottingham gradeb 0.33 0.31
Grade 1 0/11 (100) 1 0/11 (100) 1
Grade 2 5/30 (83) – Inf. Inf. 5/30 (83) Inf. Inf.
Grade 3 3/20 (85) – inf. Inf. 2/9 (78) inf. Inf.
Estrogen receptor – – – –
Positive (≥ 1%) 7/50 (86) 1 – – – –
Negative (< 1%) 1/11 (91) 0.67 1.6 0.2 to 12.7 – – – –
Progesterone receptor
Positive (≥10%) 4/41 (37) 1 3/37 (92) 1
Negative (< 10%) 4/20 (80) 0.27 2.1 0.5 to 8.6 4/13 (69) 0.048 4.0 0.90 to 18.1
HER2
Negative (0 to 1+) 7/57 (88) 1 6/49 (88) 1
Positive (2+ to 3+) 1/4 (75) 0.46 2.1 0.3 to 17.5 1/1 (0) 0.005 11.7 1.3 to 105.1
MAI
< 10 5/41 (88) 1 4/39 (90) 1
≥ 10 3/19 (66) 0.66 1.4 0.3 to 5.8 3/10 (70) 0.09 3.4 0.8 to15.2
MAI
< 3 2/16 (88) 1 2/16 (88) 1
≥ 3 6/44 (86) 0.89 1.1 0.2 to 5.5 5/33 (85) 0.80 1.2 0.2 to 6.4
PPH3
< 13 3/35 (91) 1 3/35 (91) 1
≥ 13 5/26 (81) 0.26 2.2 0.5 to 9.4 4/15 (73) 0.12 3.1 0.7 to 14.0
Ki67
< 15 0/26 (100) 0/25 (100) 1
≥ 15 8/34 (77) 0.008 – – 7/24 (71) 0.003 a a
Ki67
< 30 3/38 (92) 1 3/37 (92) 1
≥ 30 5/22 (77) 0.093 3.2 0.8 to 13.4 4/12 (67) 0.023 4.8 1.1 to 21.8
TILs
Negative (< 10%) 2/13 (85) 7/55 (87) 1
Positive (≥10%) 6/48 (88) 0.77 1.4 0.2 to 3.9 1/6 (83) 0.75 2.2 0.24
Luminal statusc
Luminal A 3/39 (92) 2/28 (93)
Luminal B 5/22 (77) 0.091 3.2 0.77 to 13.5 5/22 (77) 0.11 3.5 0.68 to 18.1
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The observed inferior RFS for ER-positive T2 tumors
suggests that larger tumor size may influence the extent to
which cancer cells activate all necessary features to pro-
mote the epithelial-mesenchymal transition (EMT) [42]
and seed out micro-metastases. These processes turn into
clinically overt relapses after some years [43]. This is in
line with other research that has found a positive correl-
ation between tumor size and relapse [44], and between
tumor size and the development of endocrine resistance
[45]. A crucial question is to what extent the pre-operative
carbohydrate load to patients in the present study pro-
moted the EMT process in the T2-T3 tumors and created
more micro-metastases [46, 47]. Importantly, increased
signaling through the insulin/IGF axis is known to pro-
mote both the EMT process [48] and chemotaxis [49],
which increases the risk for minimal residual disease to
occur. Furthermore, the pre-operative carbohydrates may
have been administered in a critical window of the can-
cer’s life cycle. The number of liberated circulating tumor
cells (CTCs) from the primary tumor sharply increases
during surgery [50]. Thus, the administered carbohydrates
may have given the CTCs systemic biological support with
a triple survival benefit through the Warburg effect [12],
the insulin/IGF-1 axis [51], and paracrine signaling with
distant adipocytes [11]. Furthermore, increased IR/IGF-
signaling promotes protein synthesis in the same way the
PR pathway does. Consequently, the upregulation of IR/
IGF-signaling will suppress the transcription of PR in the
cell [52], which is considered to be part of the endocrine
switch. Moreover, dietary carbohydrates may down-
regulate the gene expression of PR through epigenetic
mechanisms [53]. These mechanisms support our finding
of less PR-positivity in the carbohydrate arm. Taken to-
gether, these components of the endocrine switch make
CTCs more resilient to the adjuvant endocrine treatment
following surgery [9, 54]. The present study seems to sup-
port the novel principle of manipulating the perioperative
nutrient status for adjuvant treatment purposes. Recently,
the complete opposite situation with a postoperative low
carbohydrate/ketogenic diet was advocated in pancreato-
biliary cancer surgery as an option for adjuvant anti-
cancer therapy [55].
As the distribution of larger tumor sizes was skewed
to the carbohydrate group, there may be another
Table 5 Univariable analysis of relapse-free survival (Continued)
Whole cohort (n = 61) ER positive patients (n = 50)
Characteristics Event/at risk (% survival) Log rank P HR 95% CI Event/at risk (% survival) Log rank P HR 95% CI
Chemotherapy
Yes 6/29 (79) 1 5/20 (75) 1
No 2/32 (94) 0.096 0.28 0.06 to 1.4 2/30 (93) 0.069 0.25 0.05 to 1.3
Radiotherapy
Yes 6/43 (86) 1 5/38 (87) 1
No 2/17 (88) 0.90 0.91 0.18 to 4.5 2/12 (83) 0.72 1.4 0.26 to 7.0
Endocrine Therapy
Yes 7/39 (82) 1 6/36 (83) 1
No 1/22 (96) 0.15 0.24 0.03 to 2.0 1/14 (93) 0.38 0.40 0.05 to 3.3
BMI-25d
< 25 3/31 (90) 1 3/26 (89) 1
≥ 25 4/23 (83) 0.40 1.9 0.42 to 8.4 3/20 (85) 0.70 1.4 0.28 to 6.8
BMI-75pe
< 75p 4/41 (90) 1 4/36 (89) 1
≥ 75p 3/13 (77) 0.201 2.57 0.57 to 11.5 2/10 (80) 0.417 1.99 0.36 to 10.9
Smoking
-Never smoked 4/15 (73) 1 3/12 (87) 1
-Former smoker 1/23 (96) 0.22 0.025 to 2.00 1/20 (95) 0.26 0.027 to 2.5
-Ongoing smoking 1/14 (93) 0.065 0.14 0.015 to 1.22 1/12 (92) 0.15 0.17 0.017 to 1.6
BMI Body mass index, HRT Hormonal replacement therapy, T Tumor size in mm or category, N Pathological lymph node status, LN Lymph node, N0 Node
negative, N+ Node positive (assessed by pathologists), HER-2 Human epidermal growth factor receptor 2, MAI Mitotic activity index, TILs Tumor infiltrating
leucocytes, PPH3 Phosphorylated phospho-histone 3
aHR (95% CI) was not computed, as the equation did not converge, and no events occurred in one or more categories
bHistological grading was performed according to the Nottingham algorithm
cLuminal A = ER+/HER2−/Ki67 < 15% and Luminal B = ER+/HER2−/Ki67 ≥ 15% or ER+/HER2 +
dBMI-25 represents a dichotomized BMI < 25 or ≥ 25 on the BMI scale
eBMI-75p represents a dichotomized BMI with cut off < /≥ 75 percentile, i.e., </≥ 26.8 on the BMI scale
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explanation than statistical chance. As the carbohydrates
affected proliferation, they may have also affected the
growth of tumor cells in the tumor periphery, where the
MAI is measured. This may have resulted in more blurry
demarcations of the tumor, which then interferes with
the accuracy of measuring the tumor size. Thus, the in-
creased tumor size in the carbohydrate group may have
a biological basis.
The inferior prognosis of patients who received the
carbohydrate load and had T2 tumors requires some re-
flection. Patients with higher levels of insulin c-peptide
may be more responsive not only to the carbohydrate
loading they received in the present study, but also to
carbohydrates in every meal they consume during the
period in which they receive adjuvant therapies and
thereafter. These patients may have a subclinical insulin-
resistant state, which is known to be a risk factor for
relapse from breast cancer in non-diabetic women [56].
Therefore, tumor size combined with insulin c-peptide
status may predict an increased effect of adjuvant metfor-
min or other insulin-lowering drugs in the treatment of
breast cancer patients. Metformin attenuates the systemic
biological effect of IR/IGF on tumor-promoting signaling
by improving insulin sensitivity and suppressing liver glu-
cose output, which leads to reduced levels of systemic cir-
culating insulin [14]. This further mitigates paracrine
signaling, overcoming endocrine resistance [51, 57] and
improving prognosis in breast cancer [58–61]. The
present study supports the hypothesis that adjuvant met-
formin or other insulin-lowering therapeutic interactions
may have their greatest effect in breast cancer patients
with ER-positive T2 tumors. In addition, the greatly in-
creased glucose consumption by cancer cells as measured
by positron emission tomography (PET) with the tracer
18F-deoxy-glucose (FDG) [62] identifies patients with an
inferior clinical outcome [63]. This may also serve as a
promising proxy for insulin/metformin responders.
The effect of carbohydrate loading on well-being had a
very limited clinical subjective effect in the present study
(i.e., only reduced pain on the 5th and 6th day after sur-
gery). Notably, no difference in mobilization or
hospitalization was found. This is probably due to the
short duration of the operation and the extraperitoneal
nature of the surgical procedure in breast cancer
Fig. 3 Relapse-free survival (RFS) in the carbohydrate and fasting groups. a In all ER-positive patients. b In all ER-negative patients. c In ER-
positive, T1 patients. d In ER-positive, T2 patients. Fasting group, blue solid line; carbohydrate group, red dotted line. Patients at risk are above the
X-axis with the same color coding as the treatment groups. Censored patients are marked with a + sign on the survival curves
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Table 6 Univariable analysis of breast cancer-specific survival
Variable Whole study cohort (n = 61) ER-positive patients (n = 50)
Event/at risk (% survival) Log rank P HRa 95% CI Event/at risk (% survival) Log rank P HRa 95% CI
Pre-operative randomization
Fasting 1/35 (97) 1 0/29 (100) 1
Carbohydrates 4/26 (85) 0.086 4.4 0.88 to 21.7 4/21 (81) 0.015 a a
Nodal status
N0 1/43 (98) 1/33 (82) 1
N+ 4/18 (78) 0.012 4.4 1.05 to 18.5 3/17 (82) 0.080 2.80 0.63 to 12.6
Tumor size – –
T1 0/45 (100) 1 0/40 (100) 1
T2 5/16 (69) < 0.0001 5.5 1.32 to 23.1 4/10 (60) < 0.0001 a a
Nottingham grade b 0.556 0.352
Grade 1 0/11 (100) 1 0/11 (100) 1
Grade 2 3/30 (90) a a 3/30 (90) a a
Grade 3 2/20 (90) a a 1/9 (89) a a
Estrogen receptor – – – –
Positive (≥ 1%) 4/50 (92) 1 – – – –
Negative (< 1%) 1/11 (91) 0.852 0.64 0.079 to 5.21 – – – –
Progesterone receptor
Positive (≥10%) 4/41 (90) 1 3/37 (92) 1
Negative (< 10%) 1/20 (95) 0.543 0.51 0.057 to 4.59 1/13 (92) 0.94 0.93 0.1 to 8.9
HER2
Negative (0 to 1+) 4/57 (93) 1 3/49 (94) 1
Positive (2+ to 3+) 1/4 (75) 0.248 3.37 0.38 to 30.2 1/1 (0) 0.001 11.7 1.31 to 105.1
MAI
< 10 3/41 (93) 1 3/39 (92) 1
≥ 10 2/19 (90) 0.645 1.5 0.25 to 9.1 2/10 (80) 0.23 4.1 0.6 to 29.3
MAI
< 3 1/16 (94) 1 1/16 (88) 1
≥ 3 4/44 (91) 0.735 1.46 0.16 to 13.0 3/33 (85) 0.76 1.4 0.15 to 13.8
PPH3
< 13 2/35 (94) 1 2/35 (94) 1
> 13 3/26 (89) 0.426 2.0 0.34 to 12.2 2/15 (87) 0.40 2.3 0.32 to 16.1
Ki67
< 15 0/26 (100) 1 0/25 (100) 1
≥ 15 5/34 (82) 0.040 – – 4/24 (83) 0.014 a a
Ki67
< 30 1/38 (97) 1 1/37 (95) 1
≥ 30 4/22 (82) 0.033 7.5 0.84 to 67.5 3/12 (75) 0.023 9.9 1.03 to 95.3
TILs
Negative 4/55 (93) 1 3/45 (93) 1
Positive 1/6 (83) 0.479 2.16 0.24 to 19.4 1/4 (75) 0.24 3.6 0.37 to 34.6
Luminal statusc
Luminal A 3/39 (92) 1 2/28 (93) 1
Luminal B 2/22 (91) 0.847 1.2 0.20 to 7.41 2/22 (91) 0.777 1.33 0.19 to 9.42
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Table 6 Univariable analysis of breast cancer-specific survival (Continued)
Variable Whole study cohort (n = 61) ER-positive patients (n = 50)
Event/at risk (% survival) Log rank P HRa 95% CI Event/at risk (% survival) Log rank P HRa 95% CI
Chemo therapy
Yes 5/39 (87) 1 3/20 (85) 1
No 0/22 (100) 0.089 0.22 0.024 to 1.95 1/30 (97) 0.15 0.22 0.023 to 2.10
Radiation therapy
Yes 3/43 (93) 1 2/38 (95) 1
No 2/17 (88) 0.499 1.84 0.33 to 11.0 2/12 (83) 0.19 3.9 0.48 to 24.1
Endocrine therapy
Yes 5/39 (87) 1 4/36 (89) 1
No 0/22 (100) 0.089 0.024 0 to 46.4 0/14 (100) 0.20 0.03 0 to 262
BMI-25d
< 25 1/31 (97) 1 1/26 (96) 1
≥ 25 3/23 (87) 0.177 4.19 0.44 to 40.3 2/20 (90) 0.398 2.70 0.25 to 29.8
BMI-75pe
< 75p 2/41 (95) 1 2/36 (94) 1
≥ 75p 2/13 (85) 0.218 3.20 0.45 to 22.8 1/10 (90) 0.622 1.81 0.16 to 20.0
Smoking
-Never smoked 3/15 (80) 1 2/12 (83) 1
-Former smoker 0/23 (100) 0.003 Inf. 0/20 (100) 0.003 Inf.
-Ongoing smoking 0/14 (100) 0.020 0.003 Inf 0/12 (100) 0.052 0.003 Inf.
BMI Body mass index, HRT Hormonal replacement therapy, T Pathological tumor size in mm or category, LN Lymph node, N0 Node negative, N+ Node positive
(assessed by pathologists), HER-2 Human epidermal growth factor receptor 2, MAI Mitotic activity index, TILs Tumor infiltrating leucocytes, PPH3 Phosphorylated
phospho-histone 3
aHR (95% CI) was not computed, as the equation did not converge and no events occurred in one or more categories
bHistological grading was performed according to the Nottingham algorithm
cLuminal A = ER+/HER2−/Ki67 < 15% and Luminal B = ER+/HER2−/Ki67 ≥ 15%
dBMI-25 represents a dichotomized BMI < 25 or ≥ 25 on the BMI scale
eBMI-75p represents a dichotomized BMI with cut off < /≥ 75 percentile, i.e., </≥ 26.8 on the BMI scale
Fig. 4 Breast cancer-specific survival (BCSS) in the intervention and control groups. a In all ER-positive patients. b In ER-positive, T2 patients
Fasting group, blue solid line; carbohydrate group, red dotted line. Patients at risk are above the X-axis with the same color coding as the
treatment groups. Censored patients are marked with a + sign on the survival curves
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patients. The health authorities in Norway recently in-
troduced new national guidelines for a more standard-
ized trajectory in breast cancer, without preoperative
carbohydrate loading included [64]. Day-care surgery
comprising anesthesiology medication with a short half-
life, leading to fewer side effects for the patients and an
optimized pain relief regimen, has been introduced since
this trial was performed. Thus, the present study does
not support introducing carbohydrate loading in this pa-
tient group, especially due to the worrying inferior RFS
observed in the carbohydrate group.
The strengths of the biological model described above
are that it allows changes in the breast tumor to be
assessed after manipulating the metabolic environment
pre-operatively; thus, it combines the assessment of pri-
mary tumor characteristics in concert with systemic
metabolic changes. The stable nature of insulin c-
peptide also compensated for the more short-lived insu-
lin and IGF. This may explain the more robust nature of
insulin c-peptide in the various analyses.
The present study has some weaknesses. First, the
number of patients in the intervention arm turned out
to be lower than calculated in the power analysis. This
may have introduced a type II error in the various statis-
tical analyses. Furthermore, the low number of events
and patients at risk in the various survival analyses re-
quires caution in interpreting the results. Moreover, the
unbalanced number of participants in the carbohydrate
group and fasting group may have introduced con-
founders. However, as all basic characteristics were
evenly distributed between the two study arms, the risk
for such confounders is probably quite low. In addition,
the proportion of missing data was very low, which con-
tributes to strengthening the study. Regarding tumor
markers, a pre-operative biopsy of the tumor would have
turned the patients into their own controls. Thus, we
could have addressed several questions raised in the dis-
cussion, such as the increased PR-negativity in the
carbohydrate group. In future studies, pre-operative
biopsy must be included to improve the internal validity
of the trial.
Finally, the external validity of the present study is lim-
ited to luminal breast cancers with T2 tumors. Thus, the
present study should be expanded in a multicenter man-
ner, but only in luminal type breast cancers without the
PROM quality of life questionnaire. Moreover, a high in-
sulin c-peptide response to a carbohydrate load may pre-
dict high risk for relapse. Future research should pursue
this clue by adding metabolomic studies to future re-
search on predictive/prognostic circulating biomarkers
for systemic relapse in the minutest state possible [65].
Conclusion
The goal of this study was to investigate the influence of
carbohydrates on the biological characteristics of breast
cancer. Our working hypothesis was that pre-operative
carbohydrate loading affects proliferation and clinical
outcome. In the carbohydrate-loading group, the levels
of insulin and insulin-c-peptide were increased, whereas
those of IGFB3 were decreased. We found that there
were more ER+ patients with MAI ≥ 10 among patients
who received pre-operative carbohydrate loading than
among those who fasted. In addition, the proportion of
PR- patients was higher in the carbohydrate group. In
ER+ patients with tumors larger than 2 cm (T2), carbo-
hydrate loading seemed to affect clinical outcome with
significantly decreased RFS, BCSS, and OS. Only RFS
had enough events to enter into a Cox regression model,
in which carbohydrate/fasting status and tumor size
were the only independent explanatory factors. However,
Fig. 5 Overall survival (OS) in the intervention and control groups. a In all ER-positive patients. b In ER-positive, T2 patients. Fasting group, blue
solid line; carbohydrate group, red dotted line. Patients at risk are above the X-axis with the same color coding as the treatment groups.
Censored patients are marked with a + sign on the survival curves
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because this study was not powered for survival out-
comes, these analyses must be regarded as suggestive. In
addition, caution is needed when interpreting the results
due to the small sample size and relatively short follow-
up. Intriguingly, the decreased expression of PR in the
carbohydrate-loaded group suggests the development of
endocrine resistance through signaling via membrane-
bound receptors, opening up another possibility for the
change in clinical outcome than increased proliferation.
Taken together, the results of this study indicate that
per-oral carbohydrates given pre-operatively may influ-
ence both systemic and tumor biology to the benefit of
breast cancer cells. Thus, explorative metabolic investi-
gations that focus on identifying novel biomarkers asso-
ciated with the observed impairment in clinical outcome
are warranted.
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